Opendata, web and dolomites

mfloDx SIGNED

Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mfloDx project word cloud

Explore the words cloud of the mfloDx project. It provides you a very rough idea of what is the project "mfloDx" about.

983    pilot    diagnoses    antibiotic    rapid    expenditure    countries    tools    unnecessary    addressable    frac14    times    undergo    untreatable    care    point    suffering    accurate    96    life    treat    patients    curtail    15    killed    prescriptions    urgently    minimdr    global    time    costly    power    92    showed    lag    detection    million    drug    diagnostics    33    inappropriate    100    suggest    grow    tests    efficiency    2024    treatments    2030    bacteria    prescription    population    worldwide    prevent    platform    identification    regimens    world    rate    flourishing    mdr    diagnostic    months    market    generation    health    resistant    tbplus    infections    molecular    thereby    spreading    32k    incorrect    strains    projected    six    hours    faulty    organization    thousands    euros    recommend    stop    tuberculosis    mid    recommended    first    forms    tb    2015    commercial    treatment    afflicted    spread    appropriate    2000    estimates    trained    alarming    people    close    incomplete    billion    reduce    mflodx    tens    diagnosis    antibiotics    specificity    infects    patient    income   

Project "mfloDx" data sheet

The following table provides information about the project.

Coordinator
EMPE DIAGNOSTICS AB 

Organization address
address: KAROLINSKA ISTITUTE SCIENCE PARK NOBELS VAG 16
city: STOCKHOLM
postcode: 171 65
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPE DIAGNOSTICS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

Tuberculosis (TB) killed 33 million people worldwide in 2000-2015 and infects an estimated ¼ of the world population. Drug-resistant forms of TB are flourishing at an alarming rate due to faulty diagnosis and widespread prescription of incorrect antibiotics. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of untreatable TB forms. Simple, low cost diagnostic tools are needed to enable point-of-care testing in low- and mid-income countries. mfloDx is a low-cost, simple diagnostic platform that can identify close to 100% of drug resistant TB cases. Pilot tests of the first product, miniMDR-TB, showed the efficiency and specificity to be 92-96% in agreement with that of another molecular test recommended by the World Health Organization. Our next-generation mfloDx products, MDR-TB and MDR-TBplus, are expected to have close to 100% MDR-TB identification power. The low cost of mfloDx tests will enable market uptake in highly afflicted developing countries, and thereby help to stop the loss of life, the spread of antibiotic-resistant infections, and prevent unnecessary costs. Projected global expenditure on diagnosis and treatment of TB will reach €983 billion between 2015-2030. The addressable market for TB diagnostics is projected to grow to €3.1 billion by 2024. Available commercial diagnostics for MDR-TB often deliver incomplete diagnoses and require long lag times, costly equipment (€15-32K), and highly trained personnel to recommend prescriptions. As a result, less than one-third of new TB patients undergo testing to determine appropriate antibiotic treatments. Our estimates suggest that mfloDx would reduce the treatment costs per MDR-TB patient by tens of thousands of euros and diagnosis time from about six months to two hours. This would avoid costly and inappropriate antibiotic regimens, reduce patient suffering, and curtail the spread of drug-resistant bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MFLODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MFLODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More